Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

Top pharma trends and predictions for 2024

Looking at the role Gen AI and cutting-edge digital platforms will play in healthcare over the coming year

- PMLiVE

OPEN X Health launches to provide data-driven creativity to the pharmaceutical industry

OPEN X Health launches to provide data-driven creativity to the pharmaceutical industry

OPEN Health

- PMLiVE

GSK partners with DNA specialist Elegen to advance medicines and vaccines

GSK will leverage Elegen’s cell-free synthetic DNA production technology

- PMLiVE

Takeda’s HyQvia receives EC approval for rare neuromuscular disorder CIDP

HyQvia can now be used as a maintenance therapy for patients of all ages with CIDP

- PMLiVE

Merck shares positive results for Keytruda in phase 3 kidney cancer study

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Study suggests simple blood test could spare brain cancer patients risky surgery

The TriNetra-Glio test isolates broken-free tumour cells from the circulating tumour in the blood

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

The secret of the superhuman is you (and AI)

Unlocking future-readiness with three essential human skills

- PMLiVE

GSK’s Omjjara approved by EC to treat myelofibrosis patients with anaemia

About 40% of myelofibrosis patients have moderate-to-severe anaemia at the time of diagnosis

- PMLiVE

UKHSA publishes five-year strategy to detect risk-posing pathogens in UK

The strategy will help to improve the UK's response to infectious disease threats

- PMLiVE

Novavax’s XBB.1.5-adapted COVID-19 vaccine receives MHRA approval

Individuals in the UK aged 12 years and older will be eligible to receive Nuvaxovid XBB.1.5

- PMLiVE

Survey of US oncologists highlights advanced lung cancer research gaps  

Non-small cell lung cancer is responsible for approximately 85% of all lung cancers

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links